Literature DB >> 16433872

Pharmacokinetic-pharmacodynamic modelling of QT interval prolongation following citalopram overdoses.

Lena E Friberg1, Geoffrey K Isbister, Stephen B Duffull.   

Abstract

AIMS: To develop a pharmacokinetic-pharmacodynamic model describing the time-course of QT interval prolongation after citalopram overdose and to evaluate the effect of charcoal on the relative risk of developing abnormal QT and heart-rate combinations.
METHODS: Plasma concentrations and electrocardiograph (ECG) data from 52 patients after 62 citalopram overdose events were analysed in WinBUGS using a Bayesian approach. The reported doses ranged from 20 to 1700 mg and on 17 of the events a single dose of activated charcoal was administered. The developed pharmacokinetic-pharmacodynamic model was used for predicting the probability of having abnormal combinations of QT-RR, which was assumed to be related to an increased risk for torsade de pointes (TdP).
RESULTS: The absolute QT interval was related to the observed heart rate with an estimated individual heart-rate correction factor [alpha = 0.36, between-subject coefficient of variation (CV) = 29%]. The heart-rate corrected QT interval was linearly dependent on the predicted citalopram concentration (slope = 40 ms l mg(-1), between-subject CV = 70%) in a hypothetical effect-compartment (half-life of effect-delay = 1.4 h). The heart-rate corrected QT was predicted to be higher in women than in men and to increase with age. Administration of activated charcoal resulted in a pronounced reduction of the QT prolongation and was shown to reduce the risk of having abnormal combinations of QT-RR by approximately 60% for citalopram doses above 600 mg.
CONCLUSION: Citalopram caused a delayed lengthening of the QT interval. Administration of activated charcoal was shown to reduce the risk that the QT interval exceeds a previously defined threshold and therefore is expected to reduce the risk of TdP.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16433872      PMCID: PMC1884996          DOI: 10.1111/j.1365-2125.2005.02546.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  33 in total

Review 1.  The role of activated charcoal and gastric emptying in gastrointestinal decontamination: a state-of-the-art review.

Authors:  G Randall Bond
Journal:  Ann Emerg Med       Date:  2002-03       Impact factor: 5.721

2.  Inhibitory actions of the selective serotonin re-uptake inhibitor citalopram on HERG and ventricular L-type calcium currents.

Authors:  Harry J Witchel; Vijay K Pabbathi; Giovanna Hofmann; Ashok A Paul; Jules C Hancox
Journal:  FEBS Lett       Date:  2002-02-13       Impact factor: 4.124

3.  An evaluation of the impact of gender and age on QT dispersion in healthy subjects.

Authors:  H Tran; C M White; M S Chow; J Kluger
Journal:  Ann Noninvasive Electrocardiol       Date:  2001-04       Impact factor: 1.468

Review 4.  The QT interval and torsade de pointes.

Authors:  A J Moss
Journal:  Drug Saf       Date:  1999       Impact factor: 5.606

5.  Relation between QT and RR intervals is highly individual among healthy subjects: implications for heart rate correction of the QT interval.

Authors:  M Malik; P Färbom; V Batchvarov; K Hnatkova; A J Camm
Journal:  Heart       Date:  2002-03       Impact factor: 5.994

6.  Quantitative relationship between myocardial concentration of tacrolimus and QT prolongation in guinea pigs: pharmacokinetic/pharmacodynamic model incorporating a site of adverse effect.

Authors:  T Minematsu; H Ohtani; Y Yamada; Y Sawada; H Sato; T Iga
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-12       Impact factor: 2.745

Review 7.  Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: an overview.

Authors:  Fabrizio De Ponti; Elisabetta Poluzzi; Andrea Cavalli; Maurizio Recanatini; Nicola Montanaro
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

8.  Citalopram in fatal poisoning cases.

Authors:  Birgitta Jonasson; Tom Saldeen
Journal:  Forensic Sci Int       Date:  2002-03-28       Impact factor: 2.395

Review 9.  Drug-induced torsades de pointes and implications for drug development.

Authors:  Robert R Fenichel; Marek Malik; Charles Antzelevitch; Michael Sanguinetti; Dan M Roden; Silvia G Priori; Jeremy N Ruskin; Raymond J Lipicky; Louis R Cantilena
Journal:  J Cardiovasc Electrophysiol       Date:  2004-04

Review 10.  The impact of drug-induced QT interval prolongation on drug discovery and development.

Authors:  Bernard Fermini; Anthony A Fossa
Journal:  Nat Rev Drug Discov       Date:  2003-06       Impact factor: 84.694

View more
  30 in total

1.  The pharmacokinetics of sertraline in overdose and the effect of activated charcoal.

Authors:  Joyce M Cooper; Stephen B Duffull; Ana S Saiao; Geoffrey K Isbister
Journal:  Br J Clin Pharmacol       Date:  2015-02       Impact factor: 4.335

2.  Application of pharmacokinetic-pharmacodynamic modelling in management of QT abnormalities after citalopram overdose.

Authors:  Geoffrey K Isbister; Lena E Friberg; Stephen B Duffull
Journal:  Intensive Care Med       Date:  2006-05-10       Impact factor: 17.440

3.  Real Patient and its Virtual Twin: Application of Quantitative Systems Toxicology Modelling in the Cardiac Safety Assessment of Citalopram.

Authors:  Nikunjkumar Patel; Barbara Wiśniowska; Masoud Jamei; Sebastian Polak
Journal:  AAPS J       Date:  2017-11-27       Impact factor: 4.009

4.  Population pharmacokinetics and pharmacodynamics of escitalopram in overdose and the effect of activated charcoal.

Authors:  Freek van Gorp; Stephen Duffull; L Peter Hackett; Geoffrey K Isbister
Journal:  Br J Clin Pharmacol       Date:  2012-03       Impact factor: 4.335

Review 5.  Drug induced QT prolongation: the measurement and assessment of the QT interval in clinical practice.

Authors:  Geoffrey K Isbister; Colin B Page
Journal:  Br J Clin Pharmacol       Date:  2013-07       Impact factor: 4.335

6.  Model-based evaluation of drug-induced QTc prolongation for compounds in early development.

Authors:  Vincent F S Dubois; Huixin Yu; Meindert Danhof; Oscar Della Pasqua
Journal:  Br J Clin Pharmacol       Date:  2015-01       Impact factor: 4.335

7.  A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas.

Authors:  Douglas W Sborov; Alessandro Canella; Erinn M Hade; Xiaokui Mo; Soun Khountham; Jiang Wang; Wenjun Ni; Ming Poi; Christopher Coss; Zhongfa Liu; Mitch A Phelps; Amir Mortazavi; Leslie Andritsos; Robert A Baiocchi; Beth A Christian; Don M Benson; Joseph Flynn; Pierluigi Porcu; John C Byrd; Flavia Pichiorri; Craig C Hofmeister
Journal:  Leuk Lymphoma       Date:  2017-03-07

8.  Assessing QT/QTc interval prolongation with concentration-QT modeling for Phase I studies: impact of computational platforms, model structures and confidence interval calculation methods.

Authors:  Jingtao Lu; Jianguo Li; Gabriel Helmlinger; Nidal Al-Huniti
Journal:  J Pharmacokinet Pharmacodyn       Date:  2018-03-19       Impact factor: 2.745

Review 9.  The role of concentration-effect relationships in the assessment of QTc interval prolongation.

Authors:  Nicholas P France; Oscar Della Pasqua
Journal:  Br J Clin Pharmacol       Date:  2015-01       Impact factor: 4.335

Review 10.  Activated charcoal for acute poisoning: one toxicologist's journey.

Authors:  Kent R Olson
Journal:  J Med Toxicol       Date:  2010-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.